Novo Nordisk's Ozempic potentially investigated for rare eye condition

featured-image

Mario Tama Denmark's drug regulator has asked the European Medicine Agency's safety committee to evaluate two studies that found a potential link between Novo Nordisk's ( NVO ) type 2 diabetes drug Ozempic (semaglutide) and a rare eye condition. The Danish Medicines Agency said.